Current status of low‐density lipoprotein cholesterol for primary prevention of coronary artery disease in late‐stage elderly persons with type 2 diabetes mellitus: A retrospective, single‐center study. Issue 9 (19th May 2022)

• Record Type: Journal Article
• Authors: Yamamoto, Yuki; Ito, Jun; Ito, Kei; Fujii, Masanao; Nakajima, Rikako; Saito, Kazumi; Yagyu, Hiroaki
• Is Part Of: Journal of diabetes investigation. Volume 13:Issue 9(2022)
• Page Start: 1567
• Page End: 1576
• Publication Date: 2022-05-19
• Subjects: Late‐stage elderly -- Low‐density lipoprotein cholesterol -- Type 2 diabetes mellitus; Diabetes -- Periodicals; Diabetes -- Research -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462005
• DOI: 10.1111/jdi.13823
• Languages: English
• ISSNs: 2040-1116

Abstract

Abstract: Aims/Introduction: The importance of low‐density lipoprotein cholesterol (LDL‐C) in the primary prevention of cardiovascular disease has recently been reported in the population aged ≥75 years with hypercholesterolemia. Therefore, the current status of LDL‐C management for primary prevention of coronary artery disease in patients aged ≥75 years with type 2 diabetes mellitus was investigated. Materials and Methods: A total of 124 patients aged ≥75 years who had type 2 diabetes mellitus, but no coronary artery disease, were investigated. The patients' background characteristics, LDL‐C, glycemic status, ankle‐brachial index and cardio‐ankle vascular index were compared between patients taking and not taking LDL‐C‐lowering agents, such as hydroxymethylglutaryl‐CoA reductase inhibitors (statins) and ezetimibe. The details of the antihyperlipidemic and antidiabetic agents used in the present study were also examined. Results: LDL‐C was significantly lower in patients taking LDL‐C‐lowering agents (LDLCLT[+]) than in patients not taking them (LDLCLT[−]), although LDL‐C was maintained <120 mg/dL in both groups (93.0 mg/dL vs 102.1 mg/dL). Approximately half of the cases in the LDLCLT(+) group received moderate‐intensity statins, with pitavastatin being the most prescribed statin. Glycated hemoglobin was significantly lower in the LDLCLT(+) group than in the LDLCLT(−) group (6.9% vs 7.3%). Sodium‐glucose transporter 2 inhibitors were more frequently used in the LDLCLT(+) group than in the LDLCLT(−) group. The ankle‐brachial index/cardio‐ankle vascular index did not differ between the groups. Conclusion: Low‐density lipoprotein cholesterol was properly managed for primary prevention of coronary artery disease in patients aged ≥75 years with type 2 diabetes mellitus regardless of the presence or absence of LDL‐C‐lowering agents. Abstract : Low‐density lipoprotein cholesterol was properly managed by any of the treatment methods in late‐stage elderly persons with type 2 diabetes mellitus, and primary prevention for coronary artery disease could be continued regardless of the presence or types of low‐density lipoprotein cholesterol‐lowering agents by selecting the appropriate treatments.